Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genfit’s Post-NASH Plans Center On ACLF, Cholestatic Liver Disease

Executive Summary

After last year’s Phase III failure in NASH, Genfit sees big opportunity in acute on chronic liver failure (ACLF), potentially with antiviral NTX. Its ongoing Phase III program in PBC as also is a potential revenue-driver.

You may also be interested in...



Intercept Drug’s Market Standing In PBC Undermined By Safety Woes

A second FDA safety labeling update for Intercept’s Ocaliva might open a market opportunity in second-line PBC for Phase III candidates at CymaBay and Genfit.

S&E Briefs: The Good and The Bad Of COVID-19 On Biotech's Top Line

Regeneron's COVID-19 antibody cocktail helped drive 38% growth for the company, while Global Blood Therapeutics' Oxbryta continues to face headwinds and Horizon focuses on relaunches.

FDA Releases Latest Product-Specific Guidances

The latest tranche of product-specific guidances for generic development has been published by the US FDA.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel